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NF-B1 p105 functions both as a precursor of NF-B1 p50 and as a cytoplasmic inhibitor of NF-B.
Following the stimulation of cells with tumor necrosis factor alpha (TNF-), the IB kinase (IKK) complex
rapidly phosphorylates NF-B1 p105 on serine 927 in the PEST region. This phosphorylation is essential for
TNF- to trigger p105 degradation, which releases the associated Rel/NF-B subunits to translocate into the
nucleus and regulate target gene transcription. Serine 927 resides in a conserved motif (Asp-Ser927-Gly-Val-
Glu-Thr-Ser932) homologous to the IKK target sequence in IB. In this study, TNF--induced p105 prote-
olysis was revealed to additionally require the phosphorylation of serine 932. Experiments with IKK1/ and
IKK2/ double knockout embryonic fibroblasts demonstrate that the IKK complex is essential for TNF- to
stimulate phosphorylation on p105 serines 927 and 932. Furthermore, purified IKK1 and IKK2 can each
phosphorylate a glutathione S-transferase–p105758-967 fusion protein on both regulatory serines in vitro.
IKK-mediated p105 phosphorylation generates a binding site for TrCP, the receptor subunit of an SCF-type
ubiquitin E3 ligase, and depletion of TrCP by RNA interference blocks TNF--induced p105 ubiquitination
and proteolysis. Phosphopeptide competition experiments indicate that TrCP binds p105 more effectively
when both serines 927 and 932 are phosphorylated. Interestingly, however, TrCP affinity for the IKK-
phosphorylated sequence on p105 is substantially lower than that on IB. Thus, it appears that reduced p105
recruitment of TrCP and subsequent ubiquitination may contribute to delayed p105 proteolysis after TNF-
stimulation relative to that for IB.
NF-B transcription factors play an important role in the
regulation of genes involved in immune and inflammatory re-
sponses, apoptosis, and development (7, 11). Mammals express
five NF-B proteins that bind DNA as homo- and hetero-
dimers: RelA, RelB, c-Rel, NF-B1 p50, and NF-B2 p52 (22).
NF-B1 and NF-B2 are synthesized as large precursors of 105
kDa (p105) and 100 kDa (p100), respectively, that require
proteolytic processing by the proteasome to produce their re-
spective p50 and p52 NF-B subunits (1, 22).
Mature NF-B dimers are retained in the cytoplasm of
unstimulated cells through their interaction with a family of
inhibitory proteins, termed IBs (7). A number of agonists ac-
tivate NF-B, including proinflammatory cytokines, lipopoly-
saccharide, double-stranded RNA, and the viral transactivator
Tax. These stimuli induce IB phosphorylation via the IB
kinase (IKK) complex, which contains two related kinases,
IKK1 (IKK) and IKK2 (IKK), and a structural subunit,
NEMO (IKK). This triggers IB ubiquitination and subse-
quent proteolysis by the proteasome (11). NF-B dimers are
thereby released to translocate into the nucleus, where their
transcriptional activity is also regulated by phosphorylation (7).
The NF-B1 precursor p105 functions as an IB due to the
presence of ankyrin repeats in its C terminus and retains as-
sociated p50, c-Rel, and RelA in the cytoplasm (16, 20). Two
proteolytic pathways control cellular levels of p105: limited
(processing to p50) and complete (degradation) (11). Follow-
ing the stimulation of cells with proinflammatory cytokines,
such as tumor necrosis factor alpha (TNF-) or interleukin-1
(IL-1), p105 is phosphorylated and then more rapidly proteo-
lysed by the proteasome (14–16). This predominantly results in
accelerated p105 degradation, rather than increased process-
ing to p50, which is largely a constitutive process (9, 24). Freed
Rel subunits translocate into the nucleus to modulate target
gene transcription. Analysis of knockout mice which lack the
C-terminal (IB-like) half of p105 while still expressing p50 has
revealed an essential role for p105 in the proper regulation of
p50 homodimers, which is required for the correct control of
inflammatory responses (10).
The C-terminal PEST domain of p105 contains a conserved
motif (Asp-Ser927-Gly-Val-Glu-Thr-Ser932) which is homolo-
gous to the IKK target sequence in IB (Fig. 1A) (8, 21). Our
laboratory has recently demonstrated that phosphorylation of
serine 927 is essential for the signal-induced degradation of
p105 triggered by either IKK2 overexpression or stimulation of
cells with TNF- (21). Mutation of serine 932 to alanine was
also found to reduce the rate of proteolysis triggered by IKK2
overexpression. In the present study, the role of serine 932 in
signal-induced degradation was investigated in more detail.
These experiments reveal that the phosphorylation of both
serine 927 and serine 932 by the IKK complex is essential for
TNF- to trigger p105 ubiquitination and proteolysis.
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MATERIALS AND METHODS
cDNA constructs and antibodies. cDNAs encoding hemagglutinin (HA)
epitope-tagged p105 and serine-to-alanine point mutant HA-p105 derivatives
were described in an earlier study (21). For transient transfection experiments,
these were subcloned into the pcDNA3 expression vector (Invitrogen Corp.),
whereas the pMX-1 expression vector (Ingenius) was used to generate stably
transfected HeLa cell lines. Expression vectors encoding Flag-epitope-tagged
IKK2 (FL-IKK2), TrCP1 (FL-TrCP1), and TrCP2 (FL-TrCP2) have been
described previously (17, 23).
HA-p105 was immunoprecipitated using 12CA5 monoclonal antibody (MAb)
and detected in Western blots with a commercial anti-HA MAb (3F10; Roche
Molecular Biochemicals). Endogenous p105 was immunoprecipitated and de-
tected in Western blots by using the anti-p105C antibody, which recognizes the
C terminus of human p105 (21). The anti-phospho-S927–p105 antibody has been
described in previous work (21). To generate the anti-phospho-S932–p105 anti-
body, a peptide was synthesized corresponding to residues 922 through 935 of
human p105 in which serine 932 was phosphorylated. After high-pressure liquid
chromatography purification, this phosphopeptide was coupled to keyhole limpet
hemocyanin (Pierce) and injected into rabbits. For use in Western blots, immu-
noglobulin G was isolated from 4 ml of antiserum by using protein G-Sepharose
(Amersham Bioscience) and then affinity purified on a column of Affi-Gel 10
(Bio-Rad) coupled to 10 mg of phosphopeptide after first passing through an
Affi-Gel 10 column coupled to 10 mg of unphosphorylated peptide from residues
922 to 935. Antibodies recognizing IB (sc-371; Santa Cruz), TrCP1 and
TrCP2 (sc-8863; Santa Cruz), and the Flag epitope (M2 MAb; Sigma) were
purchased from the indicated suppliers. Anti-glutathione S-transferase (GST)
MAb was kindly provided by Steve Dillworth (Hammersmith Hospital, London,
United Kingdom).
Cell culture and stable transfections. HeLa cells (Ohio subline from the
European Collection of Cell Cultures) and mouse embryonic fibroblasts (EFs)
were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen
Corp.) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine,
penicillin (100 U/ml), and streptomycin (50 U/ml). For NIH 3T3 fibroblasts, 10%
newborn calf serum was substituted for FCS. IKK1 and IKK2 double knockout
(IKK1/2/) EFs were generously provided by Mark Schmitt and Inder Verma
(The Salk Institute, San Diego, Calif.) (13).
The generation of stably transfected HeLa cells was carried out as described
previously (21). Expression of HA-p105 was assessed by Western blotting.
Protein analyses. To analyze HA-p105 proteolysis in stably transfected HeLa
clones, cells were plated at 6  105 per well of a six-well plate (Nunc). After 18 h
in culture, cells were washed with phosphate-buffered saline and cultured in
methionine- and cysteine-free minimal essential Eagle’s medium (Sigma) for 90
min. Cells were pulse-labeled with 2.65 MBq of [35S]methionine-[35S]cysteine
(Pro-Mix; Amersham Bioscience) for 45 min and chased for the indicated times
in complete medium (DMEM plus 2% FCS) alone (control) or complete me-
dium supplemented with TNF- (20 ng/ml; Amersham Bioscience). Cells were
lysed in buffer A (1% NP-40, 50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM
EDTA, 50 mM NaF, 1 mM Na3VO4, 2 mM Na4P2O7, plus a cocktail of protease
inhibitors [Roche]) supplemented with 0.1% sodium dodecyl sulfate (SDS) and
0.5% deoxycholate (RIPA buffer), and HA-p105 was immunoprecipitated as
described previously (3). Labeled bands were quantified by laser densitometry
(calibrated imaging densitometer; Bio-Rad). Pulse-chase experiments were car-
ried out at least three times with similar results.
For ubiquitination experiments, HeLa cells were seeded at 2  106 cells per
90-mm-diameter dish and left in culture until confluent (1 to 2 days). Cells were
then treated with 50 M N-acetyl-L-leucyl-L-leucyl-L-norleucinal (LLnL) protea-
some inhibitor (Sigma) for 1 h and incubated for a further 15 min in the presence
of TFN- or control medium. Cells were extracted in 1.2 ml of buffer A per dish.
After centrifugation, HA-p105 was immunoprecipitated from lysates of four
dishes, resolved on a SDS–6% polyacrylamide gel electrophoresis (PAGE) gel,
and Western blotted.
Analysis of p105 phosphorylation. To analyze p105 phosphorylation on serines
927 and 932 in NIH 3T3 cells, HA-p105 was transiently expressed alone or
together with FL-IKK2 by using Lipofectamine (Invitrogen Corp.). Cells were
treated with 20 M MG132 proteasome inhibitor (Biomol Research Labs) for
the last 4 h of a 48-h culture and then lysed in buffer A. Phosphorylation was
determined by immunoblotting of anti-HA immunoprecipitates with the indi-
cated phosphopeptide-specific antibodies. Analysis of the phosphorylation of
serines 927 and 932 on endogenous p105 in HeLa cells was carried out as
described previously (21).
In vitro kinase assays. His6-IKK1 and His6-IKK2 were expressed in Sf9 insect
cells by baculovirus infection and purified to near homogeneity as described
previously (21). One hundred nanograms of recombinant IKK protein was in-
cubated at room temperature in 50 l of kinase buffer (25 mM Tris [pH 7.5],
5 mM -glycerophosphate, 2 mM dithiothreitol, 0.1 mM sodium vanadate,
10 mM MgCl2) plus 20 M ATP and 5 g of purified GST-p105758-967, GST-
p105758-967(S927A), or GST-p105758-967(S932A) protein. The reaction was
stopped by the addition of 50 l of 2 Laemmli sample buffer (12), and proteins
were Western blotted with anti-phospho-Ser927 or anti-phospho-Ser932 antibody.
Equal protein loading was confirmed by reprobing blots with an anti-GST MAb.
For in vitro phosphorylation experiments with endogenous IKK complex,
control or TNF--stimulated HeLa cells (5  106 per 90-mm dish) were lysed in
buffer A and immunoprecipitated by using anti-NEMO antibody (sc-8330; Santa
Cruz). Immunoprecipitates were washed four times in buffer A and twice in
kinase buffer. Kinase reactions were carried out as described above.
RNA interference. Depletion of endogenous TrCP expression was achieved
by RNA interference (6). Small interfering RNAs (siRNAs) for human TrCP1
and TrCP2 were synthesized by Xeragon Inc. The sequences of TrCP siRNAs
were GUGGAAUUUGUGGAACAUCTT (sense) and GAUGUUCCACAAA
UUCCACTT (antisense). At 12 to 16 h prior to transfection, 105 HeLa cells were
seeded in six-well plates (Costar) in DMEM supplemented with 10% FCS. Cells
were transfected with TrCP siRNAs (0.4 nmol per well) by using Oligo-
fectamine (Invitrogen Corp.) according to the manufacturer’s instructions. After
72-h culture, cells were stimulated with TNF- and then lysed in buffer A.
Experiments with other synthetic siRNAs demonstrated that the effects of
TrCP siRNA treatment were specific by using IB degradation as a readout
(data not shown).
Endogenous TrCP1 and TrCP2 were not detected on the Western blot of
total cell lysates. Therefore, to determine the effectiveness of siRNAs in decreas-
ing TrCP1 and TrCP2 levels, siRNAs or control transfected cells were lysed in
buffer A (1 ml) and centrifuged lysates were incubated overnight with phospho-
S32/S36 	B peptide (Fig. 1C) coupled to Affi-Gel 10 beads (Bio-Rad). Beads
were then washed four times in buffer A and isolated endogenous TrCP1 and
TrCP2 quantified by Western blotting. The same methodology was used to
determine whether endogenous TrCP1 and TrCP2 could directly bind to
p105-derived phosphopeptides (Fig. 1C).
Peptides. Synthetic p105 peptides (doubly, singly, and non-phosphorylated)
were purchased from the University of Bristol Biochemistry Department, and
IB peptides were purchased from SynPep (Dublin, Calif.). All peptides were
purified by high-pressure liquid chromatography (
90%) and verified by mass
spectrometry. The sequences of the peptides used are shown in Fig. 1C.
TrCP binding assays. FL-TrCP1 and FL-TrCP2 were synthesized to-
gether from their respective expression vectors and labeled with [35S]methionine
(Amersham Bioscience) by cell-free translation (25-l reaction volume; Promega
TNT-coupled rabbit reticulocyte system). GST-p105758-967 fusion protein was
phosphorylated with His6-IKK2 as described above, bound to glutathione-Sepha-
rose beads (10 l; Amersham Bioscience), and washed three times in buffer A.
Translated proteins, diluted to 200 l in buffer A, were then incubated with the
phospho-GST-p105758-967 beads overnight at 4°C with the indicated phos-
phopeptides or with no addition. Beads were washed a further four times in
buffer A, and 35S-labeled protein was visualized by autoradiography after
SDS–8% PAGE.
To determine the association of TrCP1 and TrCP2 with phospho-p105 in
vivo, HA-p105 HeLa cells were transiently transfected with vectors encoding
FL-TrCP1 and FL-TrCP2 (0.5 g each) by using Lipofectamine (Invitrogen
Corp.). After 48-h culture, cells were stimulated with TNF- for 15 min or left
unstimulated. HA-p105 was then isolated from cell lysates by immunoprecipita-
tion with anti-HA MAb, and Western blots were probed with anti-FL MAb to
detect HA-p105-associated FL-TrCP1 or FL-TrCP2.
In vitro IB ubiquitination. [35S]Methionine-labeled IB was prepared as
described previously (26) and then phosphorylated by recombinant, constitu-
tively active IKK2 (IKK2-EE) (17). Immunopurified SCFTrCP complex was
preincubated with 5 to 650 M concentrations of phosphorylated or unphos-
phorylated p105 or IB peptide (Fig. 1C) for 15 min and then mixed with
phospho-IB, E1, and E2. Ubiquitination was performed as described previ-
ously (26), and ubiquitinated products were analyzed by SDS-PAGE (8% acryl-
amide) and subsequent autoradiography.
RESULTS
Serine 932 is essential for TNF--induced p105 degrada-
tion. The Ley laboratory has previously demonstrated that a
serine 932-to-alanine mutant of HA-p105 displays delayed pro-
teolysis compared to wild-type HA-p105 when coexpressed
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with FL-IKK2 in NIH 3T3 cells. This suggested that the resi-
due might play a regulatory role in signal-induced p105 prote-
olysis (21). Since the IKK complex is essential for cytokine-
induced p105 degradation (21), it was important to determine
whether serine 932 is important for p105 proteolysis triggered
by cytokine stimulation of the endogenous IKK complex. To
investigate this, HeLa cells were transfected with plasmids
encoding HA-p105 or HA-p105(S932A) and stable clones were
isolated after G418 selection (Fig. 1B). A pulse-chase meta-
bolic labeling experiment was carried out with a representative
clone that expressed levels of HA-p105(S932A) similar to
that of a control clone expressing HA-p105. Stimulation with
TNF- increased the rate of turnover of HA-p105 as expected
(Fig. 2A and B). In contrast, TNF- stimulation consistently
had no detectable effect on the rate of proteolysis of HA-p105
(S932A). Analysis of the 90-min point confirmed that there was
no significant difference in the amount of HA-p105(S932A)
remaining  TNF- (P  0.23; n  5). However, the mobility
of the HA-p105(S932A) band was retarded and became less
distinct after TNF- stimulation, probably due to phosphory-
lation on amino acids other than serine 932 (Fig. 2B). As
reported previously (21), TNF- stimulation did not increase
the proteolysis of HA-p105(S927A) (Fig. 2A). Control exper-
iments demonstrated that IB was rapidly and completely
degraded following TNF- stimulation in the HA-p105(S932A)
clone similar to that in the wild-type HA-p105 clone, con-
firming that the TNF- signaling pathway controlling the IKK
complex was intact in the former cell line (Fig. 2C). Thus,
serine 932 is essential for TNF- to efficiently induce the pro-
teolysis of HA-p105.
It was possible that the inhibitory effect of the S932A mu-
tation on TNF--induced proteolysis of HA-p105 was due to
the indirect effects on the phosphorylation of serine 927, which
has previously been shown to be essential for the signal-in-
duced degradation of p105 (8, 21). To investigate this possi-
bility, HA-p105 was immunoprecipitated from the HA-p105
(S932A) clone with or without TNF- stimulation and Western
blotted with anti-phospho-S927-p105 antibody. TNF--induced
serine 927 phosphorylation of HA-p105(S932A) was similar to
that of wild-type HA-p105 (Fig. 2D). Thus, the S932A muta-
tion did not mediate its inhibitory effects on HA-p105 prote-
olysis by blocking the phosphorylation of serine 927.
A recent study demonstrated that recombinant IKK2 phos-
phorylated a p105917-968 fusion protein on a residue equivalent
to serine 923 in the full-length p105 protein (8). Furthermore,
proteolysis of a serine 923-to-alanine point mutant of p105 was
reduced when coexpressed in 293 cells with IKK2 and TrCP
compared to the wild-type protein. In contrast, previous ex-
periments from this laboratory did not suggest an important
role for serine 923 in degradation of HA-p105 triggered by
FL-IKK2 overexpression in NIH 3T3 fibroblasts (21). To in-
vestigate whether serine 923 is required for the cytokine-in-
duced degradation of p105, stable HeLa clones expressing HA-
p105(S923A) were generated. Stimulation of a representative
clone with TNF- increased the rate of HA-p105(S923A) pro-
teolysis to a degree similar to that for wild-type HA-p105 (Fig.
2A). Analysis of the 90-min-chase time point confirmed that
there was no significant difference in the amount of HA-p105
(S923A) remaining (65%) compared to that of wild-type HA-
p105 (60%) in TNF--stimulated cells (P  0.372; n  5).
Thus, consistent with previous data (21), serine 923 is not
required for stimulus-induced p105 degradation.
In conclusion, these data indicate an essential role for both
serines 927 and 932 in the proteolysis of p105 triggered by
TNF- stimulation, whereas serine 923 is not required for
TNF--induced p105 proteolysis.
TNF- induces the rapid phosphorylation of p105 on serine
932. The previous experiments indicate an important role for
serine 932 in p105 proteolysis triggered by stimulation with
TNF-. However, it was important to obtain direct evidence
that serine 932 was actually phosphorylated in vivo to rule out
the inhibitory effects on p105 proteolysis resulting from puta-
tive structural alterations caused by the S932A mutation. To
investigate this, rabbits were immunized with a synthetic pep-
tide corresponding to residues 922 to 935 of human p105 in
which serine 932 was phosphorylated and specific antibody was
purified on a phosphopeptide affinity column.
FIG. 1. IKK target sequences, p105 point mutants, and synthetic
phosphopeptides. (A) Schematic representation of mammalian NF-
B1 p105. The relative positions of the Rel homology domain (RHD),
nuclear localizing signal (NLS), glycine-rich region (GRR), ankyrin
repeats (vertical rectangles), death domain (DD), and PEST domain
are shown. An alignment of the IKK target sequence in the p105 PEST
region with those in IB, IB, and IBε is also shown (all human
proteins). (B) Serine-to-alanine point mutants of HA-p105. WT, wild
type. (C) Sequences of synthetic p105 and IB peptides. P, phosphor-
ylated residue.
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To initially investigate the possibility of the signal-induced
phosphorylation of p105 on serine 932, NIH 3T3 cells were
transfected with plasmids encoding wild-type HA-p105 or HA-
p105(S932A) plus FL-IKK2 or control empty vector (EV).
Cells were incubated with MG132 inhibitor for the last 4 h of
a 48-h culture to block proteasome-mediated proteolysis. HA-
p105 immunoprecipitated from cells coexpressing FL-IKK2
was clearly recognized by the anti-phospho-S932-p105 antibody
but not from cells cotransfected with EV (Fig. 3A). However,
no signal was obtained in cells cotransfected with HA-p105
(S932A) and FL-IKK2, although HA-p105(S932A) protein
was present in immunoprecipitates and phosphorylated on
FIG. 2. Serine 932 is essential for TNF- to trigger proteolysis of p105. (A) Clones of HeLa cells stably transfected with HA-p105, HA-p105
(S923A), HA-p105(S927A), or HA-p105(S932A) were metabolically pulse-labeled with [35S]methionine-[35S]cysteine (45 min) and then chased for
the indicated times in complete medium (control) or complete medium supplemented with TNF-. Anti-HA immunoprecipitates were resolved
by SDS–7.5% PAGE and revealed by fluorography. Amounts of immunoprecipitated wild-type (WT) and point-mutated HA-p105 were quantified
by laser densitometry (mean  standard error of the mean; n  5). (B) HeLa cells stably transfected with either HA-p105 or HA-p105(S932A)
were analyzed by pulse-chase metabolic labeling as described for panel A. Anti-HA immunoprecipitates (Ip) were resolved by SDS–7.5% PAGE
and revealed by fluorography. The position of HA-p105 is indicated with an arrow. (C) Cell lysates from the indicated HeLa clones with or without
TNF- stimulation (15 min) were Western blotted for endogenous IB. (D) Stably transfected HeLa cells were preincubated for 1 h with LLnL
proteasome inhibitor and then stimulated for 15 min with TNF- or control medium. Immunoprecipitates of wild-type and point-mutated HA-p105
were then sequentially Western blotted with the indicated antibodies.
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serine 927. In addition, incubation of blots with anti-phospho-
S932-p105 antibody plus S932 phosphopeptide reduced the
phospho-HA-p105 signal in FL-IKK2-cotransfected cells to
background whereas the addition of unphosphorylated peptide
had no effect (data not shown). Together, these data confirm
the specificity of the anti-phospho-S932-p105 antibody and
demonstrate that overexpression of FL-IKK2 induces the
phosphorylation of HA-p105 on serine 932. Furthermore,
these data indicate that the reduced proteolysis of HA-p105
(S932A) in response to FL-IKK2 coexpression was not the
consequence of decreased serine 927 phosphorylation (21).
Conversely, the reduced IKK2-triggered proteolysis of HA-
p105(S927A) did not result from the blockade of serine 932
phosphorylation (Fig. 3A).
To investigate whether proinflammatory cytokines induce
the phosphorylation of serine 932 of p105, HeLa cells were
preincubated with MG132 inhibitor for 30 min and then stim-
ulated for the indicated times with TNF-. Endogenous p105
was isolated from cell lysates by immunoprecipitation and then
immunoblotted with anti-phospho-S932-p105 antibody. TNF-
stimulation induced rapid serine 932 phosphorylation that
reached a maximum at 15 min and then declined (Fig. 3B,
middle panel). The kinetics of p105 serine 927 phosphorylation
after TNF- stimulation were very similar (Fig. 3B, upper
panel). Low levels of p105 phosphorylated on both serines 927
and 932 also accumulated in control unstimulated cells by 1 to
2 h, which were presumably due to basal IKK activity.
It was important to determine whether the inhibitory effect
of the S927A mutation on the TNF--induced proteolysis of
HA-p105 (21) was due to the indirect inhibition of serine 932
phosphorylation. To investigate this, HA-p105 was immuno-
precipitated from the HeLa clone expressing HA-p105(S927A)
and cultured for 1 h with LLnL proteasome inhibitor and for a
further 15 min in the presence or absence of TNF-. Western
blotting with the anti-phospho-S932-p105 antibody indicated
that HA-p105(S927A) was phosphorylated on serine 932 to a
similar degree as wild-type HA-p105 phosphorylation after
TNF- stimulation (Fig. 3C). Thus, the S927A mutation does
not inhibit the TNF- induction of HA-p105 proteolysis by
blocking serine 932 phosphorylation.
The data in this section confirm that serine 932 of p105 is
phosphorylated under stimulatory conditions that promote
p105 proteolysis and indicate that the inhibitory effect of the
S932A mutation on TNF--induced p105 proteolysis is due to
the removal of a regulatory phosphorylation site.
Serine 932 of p105 is phosphorylated by the IKK complex.
Since the IKK complex is essential for signal-induced p105
proteolysis, it was important to determine whether cytokine-
induced phosphorylation of p105 on serine 932 required the
IKK complex. To investigate this, wild-type mouse EFs and
IKK1/2 double knockout EFs (12), which lack a functional IKK
complex, were pretreated for 30 min with MG132 inhibitor and
then stimulated with TNF- for 15 min. Western blotting of
immunoprecipitated endogenous p105 indicated that TNF-
induced serine 932 phosphorylation in wild-type EF cells but
not in the IKK1/2–/– cells (Fig. 4A). TNF- also failed to
induce serine 927 phosphorylation in the IKK1/2–/– EF cells,
whereas serine 927 phosphorylation was induced in wild-type
cells. Similar experiments with IKK1 or IKK2 single-knockout
EFs demonstrated that IKK1 and IKK2 are redundant for the
TNF- induction of p105 phosphorylation on serines 927 and
932 (data not shown), consistent with the ability of TNF- to
induce p105 proteolysis in such cells (21). However, TNF--
induced phosphorylation of these residues was consistently
detected to be higher in wild-type cells than in the single
knockouts, suggesting that IKK complexes containing both
IKK1 and IKK2 are required for optimal p105 phosphoryla-
tion. TNF- induction of p38 phosphorylation in the IKK1/2–/–
FIG. 3. TNF- induces rapid phosphorylation of p105 on serine
932. (A) NIH 3T3 cells were transiently cotransfected with expression
vectors encoding wild-type (WT) HA-p105 or the indicated mutants
and IKK2 or EV and treated with MG132 proteasome inhibitor for the
last 4 h of a 48-h culture. HA-p105 was immunoprecipitated, and
isolated protein was sequentially Western blotted with anti-phospho-
Ser932 (upper gel), anti-phospho-Ser927 (middle gel), and anti-p105C
(lower gel) antibodies. Ip, immunoprecipitates. (B) HeLa cells were
preincubated for 30 min with MG132 and then stimulated for the
indicated times with TNF- or control medium (C). Immunoprecipi-
tates of endogenous p105 were then Western blotted sequentially with
the indicated antibodies. (C) HeLa cells stably transfected with the
indicated HA-p105 constructs were preincubated for 1 h with LLnL
inhibitor and then stimulated for 15 min with TNF- or control me-
dium. Anti-HA immunoprecipitates were then sequentially Western
blotted with the indicated antibodies.
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EFs was similar to that in the wild type, confirming that the
TNF- signaling was intact (data not shown). Furthermore,
transient overexpression of FL-IKK2 or FL-IKK1 and FL-
IKK2 in the IKK1/2–/– EFs strongly induced phosphorylation
of p105 on both serines 927 and 932 (Fig. 4B), supporting the
hypothesis that the defect in TNF--induced p105 phosphor-
ylation in these cells is indeed due to the lack of a functional
IKK complex.
These data raise the possibility that the IKK complex might
directly phosphorylate p105 serine 932. To investigate this, GST
fusion proteins were purified from Escherichia coli encoding
the C terminus of p105 (residues 758 to 967; GST-p105758-967)
and corresponding mutants in which the residues equivalent
to p105 serine 927 or 932 were mutated to alanine [GST-
p105758-967(S927A) and GST-p105758-967(S932A), respective-
ly]. These fusion proteins were phosphorylated in vitro with
baculovirus-expressed His6-IKK1 or His6-IKK2. Western
blotting with anti-phospho-S932-p105 antibody confirmed
that both kinases phosphorylated GST-p105758-967 and GST-
p105758-967(S927A) on serine 932, whereas no signal was de-
tected with GST-p105758-967(S932A), as expected (Fig. 4C).
Similarly, both His6-IKK1 and His6-IKK2 also phosphory-
lated serine 927 of the wild type and the S932A mutants of
GST-p105758-967 but not of the S927A mutant, as reported
previously (21). Endogenous IKK complex, purified by immu-
noprecipitation from TNF--stimulated HeLa cells, also phos-
phorylated both serine 927 and serine 932 of p105 (Fig. 4D).
Thus, p105 serine 932 is a direct target of the IKK complex in
vitro. The combined biochemical and genetic data in this sec-
tion therefore demonstrate that TNF- induces the phosphor-
ylation of both serine 927 and serine 932 of p105 via the IKK
complex.
Signal-induced phosphorylation of serine 927 and serine
932 regulates p105 ubiquitination. IKK2-induced phosphor-
ylation of p105 triggers its ubiquitination, targeting it for
proteolysis by the proteasome (8, 19). The role of the phos-
phorylation of serines 927 and 932 on TNF--induced p105
ubiquitination was therefore investigated. HeLa cells stably
transfected with HA-p105, HA-p105(S927A), or HA-p105
(S932A) were pretreated with the LLnL proteasome inhibitor
FIG. 4. The IKK complex directly phosphorylates serine 932 of p105. (A) Wild-type (WT) and IKK1/2–/– (/) EFs were pretreated with
MG132 for 30 min and then incubated for a further 30 min with TNF- or control medium. p105 was then immunoprecipitated from cell lysates
and Western blotted with the indicated antibodies. Ip, immunoprecipitates. (B) IKK1/2/ or wild-type EFs were transiently cotransfected with
the indicated expression vectors. Cells were treated with MG132 for the last 4 h of a 48-h culture. HA-p105 was isolated from cell lysates by
immunoprecipitation and immunoblotted with the antibodies shown. (C) In vitro kinase assays were carried out with baculovirus-produced purified
His6-IKK1 or His6-IKK2 (100 ng), using as substrates 5 g of wild-type or point-mutated GST-p105758-967 protein, as indicated. Phosphorylation
was assessed by sequentially immunoblotting with anti-phospho-Ser932 (upper gel) or anti-phospho-Ser927 (middle gel) antibodies. Equal loading
of fusion proteins was confirmed by reprobing blots with anti-GST MAb (lower gel). (D) HeLa cells were stimulated for 15 min with TNF- or
left unstimulated. The endogenous IKK complex was isolated from cell lysates by immunoprecipitation with an anti-NEMO antibody. Control
immunoprecipitations were carried out with nonimmune rabbit serum (NRS). Phosphorylation was assessed as described for panel C. Blots were
probed with anti-NEMO antibody to confirm that equal amounts of IKK complex were immunoprecipitated.
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for 1 h. The cells were then incubated for a further 15 min with
TNF- or left unstimulated. HA-p105, immunoprecipitated
from cell lysates with anti-HA MAb, was Western blotted with
anti-p105C antibody. TNF- stimulation promoted the appear-
ance of a high-molecular-weight ladder of more slowly migrat-
ing forms of HA-p105, characteristic of ubiquitinated p105 (8,
19), which were not visible if LLnL inhibitor was omitted (Fig.
5A). Direct immunoblotting of p105 immunoprecipitates with
antiubiquitin antibody confirmed that TNF--induced ladder-
ing was due to HA-p105 polyubiquitination (data not shown).
However, TNF- stimulation failed to induce high-molecu-
lar-weight forms of either HA-p105(S927A) or HA-p105
(S932A) (Fig. 5B). These data indicate that both the S927A
and S932A mutations block the TNF--induced ubiquitination
of p105, suggesting that the phosphorylation of both serines
927 and 932 is required for TNF- to trigger p105 ubiquitina-
tion. This is consistent with the observation that serines 927
and 932 are both essential for TNF--induced p105 proteolysis
(Fig. 2A).
TrCP is essential for the TNF- induction of p105 and
IB proteolysis. Biochemical experiments have demon-
strated that the phosphorylation of p105 by IKK creates a
binding site for TrCP1 and/or TrCP2, F-box WD40 repeat
proteins that are the receptor subunits of an SCF-type E3
ubiquitin ligase (19). In vitro experiments indicate that this
association promotes the polyubiquitination of p105 and sub-
sequent proteolysis by the proteasome (8, 19). Consistent with
this model, the transient expression of an F-box deletion mu-
tant of TrCP1, which can bind to IKK-phosphorylated p105
but cannot assemble with other SCF subunits, blocks p105
proteolysis induced by IKK2 overexpression (19).
To determine whether TNF- stimulation also induces bind-
ing of TrCP (used as a collective term referring to both
TrCP1 and TrCP2) to p105, HeLa cells stably expressing
HA-p105 were transiently transfected with expression vectors
encoding TrCP1 and TrCP2. HA-p105 was isolated by im-
munoprecipitation from lysates of cells stimulated for 15 min
with TNF- or left unstimulated. TNF- stimulation induced a
clear association between HA-p105 and both TrCP1 and
TrCP2 (Fig. 6A).
Functional experiments on the role of TrCP on p105 ubiq-
uitination have relied on purified components for in vitro ex-
periments or protein overexpression in cells (8, 19). It was
therefore important to confirm genetically that TrCP was
indeed required for TNF--induced p105 proteolysis. siRNA-
mediated gene suppression (6), based on a 21-bp double-
stranded RNA complementary to both TrCP1 and TrCP2,
was used to codeplete TrCP1 and TrCP2 from HeLa cells
stably transfected with HA-p105. Western blotting confirmed
that siRNA depleted TrCP expression to undetectable levels
(Fig. 6B, upper panel). Pulse-chase metabolic labeling revealed
that TrCP depletion blocked TNF--induced HA-p105 pro-
teolysis (Fig. 6C). TNF--induced p105 ubiquitination, as re-
vealed by the presence of high-molecular-weight p105 ladder-
ing, was also substantially reduced by TrCP depletion (Fig.
6D). In addition, TNF--induced IB proteolysis was blocked
in HeLa cells depleted of TrCP (Fig. 6B, lower panel) where-
as TNF--induced p38 phosphorylation was unaffected (data
not shown). Thus, TrCP is required for TNF- to promote
the ubiquitination and proteolysis of p105, supporting earlier
models for TrCP in regulating p105 function (8, 19). Further-
more, these experiments confirm the essential role of TrCP in
TNF--induced IB degradation (4).
The effect of TrCP depletion on TNF--induced p105
phosphorylation was also investigated. TNF--induced phos-
phorylation of p105 on serines 927 and 932 was substantially
increased in TrCP-depleted cells compared to that in the
control (Fig. 6E). This suggests that p105 phosphorylated on
serines 927 and 932 is specifically targeted for ubiquitination by
TrCP, consistent with the essential role of these residues in
TNF--induced p105 ubiquitination and proteolysis (Fig. 2A
and 5B).
Efficient binding of TrCP to p105 requires phosphoryla-
tion of both serines 927 and 932. The siRNA experiments raise
the possibility that the recruitment of TrCP to p105 requires
phosphorylation on both serines 927 and 932. A competition
FIG. 5. Serines 927 and 932 are required for TNF- to trigger p105 ubiquitination. (A) HeLa cells stably transfected with HA-p105 were
pretreated for 1 h with LLnL proteasome inhibitor or vehicle control (dimethyl sulfoxide [DMSO]). Cells were then stimulated for 15 min with
TNF- or control medium. HA-p105 was isolated from cell lysates by immunoprecipitation, resolved by SDS–6% PAGE, and then Western blotted
with anti-p105C antibody. Ip, immunoprecipitates; WT, wild type. (B) The indicated HeLa clones were pretreated with LLnL inhibitor and
stimulated with TNF- as described for that in panel A. Anti-HA immunoprecipitates were Western blotted with anti-p105C antibody.
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assay using synthetic phosphopeptides (Fig. 1C) corresponding
to residues 922 to 935 of p105 was used to directly determine
the role of p105 serine 927 and 932 phosphorylation in TrCP
binding.
For this, GST-p105758-967 fusion protein, phosphorylated in
vitro by recombinant His6-IKK2 or left untreated, was coupled
to glutathione-Sepharose beads and used as an affinity matrix
to isolate [35S]methionine-labeled TrCP1 and TrCP2 which
had been translated in vitro. As expected, the amount of
TrCP isolated by GST-p105758-967 was significantly increased
following His6-IKK2 phosphorylation compared with that for
the control unphosphorylated protein (Fig. 7A). The addition
of phosphoserine 932 p105922-935 peptide had no effect on
TrCP binding compared to no peptide (data not shown) or
FIG. 6. TrCP is required for TNF--induced p105 ubiquitination and proteolysis. (A) HeLa cells stably transfected with HA-p105 were
transiently transfected with vectors encoding FL-TrCP1 and FL-TrCP2. After 48-h culture, cells were stimulated for 15 min with TNF- or left
unstimulated. Anti-HA immunoprecipitates (Ip) were Western blotted with the indicated antibodies. FL-TrCP expression in cell lysates was
confirmed by anti-FL MAb immunoprecipitation and Western blotting. WT, wild type. (B) HeLa cells were pretreated with TrCP siRNAs
complementary to both TrCP1 and TrCP2 (TrCP) or with control buffer (TrCP). After 72 h, cells were stimulated with TNF- (15 min)
or left unstimulated and then lysed. In the upper gel, TrCP expression of unstimulated cells was determined by Western blotting of phospho-IB
peptide pulldowns. In the lower gel, cell lysates were Western blotted for IB. (C) HeLa cells stably expressing HA-p105 were pretreated as
described for panel B. Turnover of HA-p105 in TNF--stimulated and control unstimulated cells was determined by pulse-chase metabolic labeling
as done for that shown in Fig. 2. Similar results were obtained on two other occasions. (D) TrCP expression in HA-p105 HeLa cells was
suppressed by siRNA pretreatment as described for panel B. HA-p105 ubiquitination induced by 15-min TNF- stimulation was determined as
described in the legend to Fig. 5. (E) TrCP expression was decreased by siRNA treatment as described for panel B. Phosphorylation of
endogenous p105 after TNF- treatment (15 min) was determined by immunoprecipitation and Western blotting with the indicated antibodies.
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FIG. 7. Efficient binding of TrCP to p105 requires phosphorylation of p105 serines 927 and 932. (A) GST-p105758-967 fusion protein,
phosphorylated by His6-IKK2 or left unphosphorylated, was coupled to glutathione-Sepharose beads and used to affinity purify TrCP translated
and labeled with [35S]methionine in vitro. The indicated peptides were added to a final concentration of 100 g/ml during the pulldown. Isolated
TrCP was detected by autoradiography of SDS–8% PAGE gels. (B) The indicated peptides were coupled to Affi-Gel 10 beads and used as affinity
matrices to isolate from HeLa cell lysates endogenous TrCP, which was detected by Western blotting. (C and D) IB, translated and labeled
in vitro with [35S]methionine, was first phosphorylated with recombinant IKK2-EE. Labeled protein was then ubiquitinated in vitro (26) in the
presence of the indicated peptides or with no added peptide (w/o peptide). Ubiquitination of unphosphorylated IB (w/o IKK) is shown as a
negative control. IB ubiquitination was revealed by autoradiography of SDS–8% PAGE gels. (E) The extent of IB ubiquitination in vitro
(carried out as described for panel C) was quantified on a phosphorimager over a range of competing peptide concentrations.
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to the addition of unphosphorylated p105922-935 peptide. Some
inhibition of binding was detected upon addition of p105922-935
peptide phosphorylated on serine 927. However, addition of
p105922-935 peptide phosphorylated on both serines 927 and
932 completely blocked binding to TrCP.
These data suggest that p105 requires phosphorylation on
both serines 927 and 932 to most efficiently bind TrCP but
that weak binding can be achieved when only serine 927 is
phosphorylated. To investigate this possibility directly, each of
the phosphopeptides was individually coupled to Affi-Gel 10
beads and then used as affinity matrices to purify endogenous
TrCP from HeLa cell lysates. Western blotting revealed no
TrCP binding with unphosphorylated p105922-935 peptide or
phosphoserine 932 p105922-935 peptide (Fig. 7B), consistent
with the peptide competition experiment (Fig. 7A). However,
TrCP binding was detected to p105922-935 peptide phosphor-
ylated on only serine 927, but to a lesser extent than that to the
doubly phosphorylated p105922-935 peptide (Fig. 7B). These
data confirm that TrCP binds more effectively to p105 phos-
phorylated on both serines 927 and 932.
TrCP has a higher affinity for phospho-IB than phos-
pho-p105. Previous experiments have indicated that p105 and
IB are phosphorylated with very similar kinetics by IKK
after TNF- stimulation of HeLa cells (21). However, TNF-
stimulation only results in the slow and partial degradation of
p105, in contrast to IB, whose degradation is very rapid and
complete (Fig. 2C) (21). A possible explanation for this differ-
ence is that the two proteins recruit SCFTrCP with different
efficiencies after IKK-mediated phosphorylation and, as a re-
sult, are ubiquitinated at different rates.
A previously developed in vitro IB ubiquitination assay
(26) was used to compare the relative affinity of TrCP for the
IKK target sites on p105 and IB. In vitro-translated and
[35S]methionine-labeled IB was allowed to associate with
immunopurified NF-B (from HeLa cells), phosphorylated
with recombinant IKK2-EE, and subjected to TrCP-mediated
ubiquitination in a cell-free system which does not support
IB phosphorylation or proteasome-mediated degradation.
Under control conditions, phosphorylated IB, but not un-
phosphorylated IB, was efficiently converted to a polyubiq-
uitinated species (Fig. 7C, compare lane without IKK to lane
without peptide). The addition of IB28-37 peptide phosphor-
ylated on serines 32 and 36 (Fig. 1C) completely inhibited
IB ubiquitination with a 50% inhibitory concentration
(IC50) of 5 M (Fig. 7C and E). The addition of p105922-935
peptide phosphorylated on serines 927 and 932 also inhibited
IB ubiquitination but was much less efficient (IC50  25
M) than the phospho-IB28-37 peptide. The phosphoserine
927 p105922-935 peptide was even less effective (IC50  60 M)
in inhibiting IB ubiquitination, and phosphoserine 932
p105922-935 peptide had no detectable effect (Fig. 7C and E).
These data confirm that TrCP preferentially binds to p105
phosphorylated on both serines 927 and 932 and also indicate
that TrCP has a higher affinity for phospho-IB than for
phospho-p105.
The Asp-Ser927(P)-Gly-Val-Glu-Thr-Ser932(P) motif in the
PEST region of p105 is closely related to the N-terminal IKK
target sequence of IB, Asp-Ser32(P)-Gly-Leu-Asp-Ser36(P),
except for the introduction of an extra residue between the two
phosphorylated serines in p105 (Fig. 1A). To determine
whether this spacing might explain the differential affinity of
TrCP for the phospho-IB28-37 and phospho-p105922-935
peptides, an IB28-37 phosphopeptide was synthesized in
which the spacer between phosphoserines 32 and 36 was in-
creased by the introduction of an alanine residue (Fig. 1C).
This peptide was less effective in blocking IB ubiquitination
than the wild-type phospho-IB28-37 peptide (Fig. 7D) (IC50
 50 M estimated from titration experiments). This suggests
that the high affinity binding of TrCP to phosphorylated tar-
gets requires a 3-amino-acid spacing between phosphorylated
serines and that target proteins with a 4-amino-acid spacing,
such as p105, bind with lower affinity.
DISCUSSION
The experiments in this study demonstrate that phosphory-
lation of serines 927 and 932 within the PEST region of NF-
B1 p105 is essential for its degradation triggered by TNF-
stimulation (Fig. 2A). This reflects a requirement for the phos-
phorylation of both serines to promote efficient recruitment of
the E3 ubiquitin ligase SCFTrCP to phospho-p105 and subse-
quent p105 ubiquitination (Fig. 6). Furthermore, in vitro ex-
periments demonstrate that serine 927 and serine 932 are
directly phosphorylated by the IKK complex, whose expression
is necessary for the TNF--induced phosphorylation of both
serines in EF cells (Fig. 4). IL-1 stimulation also triggers both
serine 927 and 932 phosphorylation of p105, and IL-1-induced
p105 proteolysis is blocked by the mutation of either serine 927
or serine 932 to alanine (21) (data not shown). Thus, although
the signaling pathways triggered by TNF- and IL-1 are dis-
tinct (18, 25), both cytokines appear to trigger p105 proteolysis
via a common phosphorylation-based mechanism. It is likely
that p105 proteolysis induced by other agonists, such as lipo-
polysaccharide and phorbol ester (5, 14), will also involve the
phosphorylation of serines 927 and 932 by the IKK complex.
Consistent with this hypothesis, p105 proteolysis triggered by
overexpressed TPL2/Cot (3) also requires the phosphorylation
of both serines 927 and 932 (data not shown).
Heissmeyer et al. have previously suggested a regulatory role
for serine 923 (Asp-Ser923-Val-Cys-Asp-Ser927) in IKK2-in-
duced HA-p105 proteolysis in 293 cells transiently cotrans-
fected with TrCP (8). However, p105 degradation triggered
by phosphorylation by the endogenous IKK complex after
TNF- stimulation does not require serine 923 (Fig. 2A) and
an earlier study by our laboratory also failed to reveal a role for
this residue in IKK2-induced p105 proteolysis in NIH 3T3 cells
(21). Serine 923, therefore, is unlikely to be an important
physiological target of the IKK complex, and it has not yet
been demonstrated that serine 923 is actually phosphorylated
after cytokine stimulation. To investigate this directly, an an-
tibody was raised to a synthetic peptide corresponding to res-
idues 921 through 933 of human p105 in which serine 923 is
phosphorylated. Although this antibody clearly recognized
specifically the immunizing phosphopeptide on dot blots, it did
not bind to p105 phophorylated either in vivo after TNF-
stimulation or in vitro by recombinant IKK2 (data not shown).
These latter results contrast with those of Heissmeyer et al. (8),
who reported that purified IKK2 phosphorylated the recombi-
nant His6-p105
917-968 fusion protein on serine 923 in vitro. The
Ley laboratory has recently demonstrated that the efficient
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phosphorylation of p105 on both serines 927 and 932 in vitro
requires the p105 death domain (p105 residues 802 to 893),
which acts as a docking site for IKK2 (2) (data not shown). It
is possible that serine 923 of the recombinant His6-p105
917-968
fusion protein is artefactually phosphorylated by IKK2 due to
the absence of p105 death domain-IKK2 interaction, which
may be important both to ensure the efficiency of phosphory-
lation and for correct target amino acid specificity (2).
The Asp-Ser927-Gly-Val-Glu-Thr-Ser932 motif in the PEST
domain of p105 is distinct from the N-terminal IKK target
sequence of IB (Asp-Ser32-Gly-Leu-Asp-Ser36) due to the
introduction of an extra residue between the two phosphory-
lated serines in p105 (Fig. 1A). In vitro binding experiments
suggest that one functional consequence of this extra amino
acid in p105 is to significantly decrease the affinity of TrCP
for the IKK phosphorylated sequence (Fig. 7). Consistent with
this possibility, introduction of an extra amino acid between
the IKK-phosphorylated serines in IB reduces the ability of
IB phosphopeptides to block TrCP-dependent IB ubiq-
uitination (Fig. 7D). Interestingly, the IKK target sequence in
p105 is completely conserved between human, mouse, rat, and
chicken p105 (21), suggesting that the lower affinity of phos-
pho-p105 for TrCP confers some evolutionary advantage.
Presumably one consequence of this decreased binding is to
reduce the efficiency of TrCP-mediated ubiquitination of
phospho-p105 compared with that of phospho-IB. This may
explain in part the slow and partial proteolysis of p105 in
TNF--stimulated cells compared with that of IB, which is
rapidly and completely degraded (21). However, although IKK
phosphorylates p105 and IB with similar kinetics after
TNF- stimulation (21), it cannot be excluded that the IKK
complex phosphorylates IB at a higher stoichiometry than
p105, and this may also contribute to the different efficiency of
their proteolysis in TNF--stimulated cells.
Both phosphopeptide competition and pull-down experi-
ments (Fig. 7) indicate that TrCP can bind weakly when p105
serine 927 alone is phosphorylated, whereas no binding is de-
tected to a phosphoserine 932 p105 peptide. However, phos-
phorylation of both serines 927 and 932 generates a higher
affinity binding site for TrCP. Interestingly binding of
TrCP1 to phospho-IB peptides shows a similar phosphor-
ylation requirement. Thus, an IB peptide phosphorylated on
both serines 32 and 36 binds to recombinant TrCP1 with high
affinity (Kd  70 nM) whereas a peptide phosphorylated on
only serine 32 binds much more weakly (Kd  16 M) (R. Hay,
unpublished data). In contrast, binding to a phosphoserine 36
IB peptide is unmeasurable. Together these data suggest
that TrCP has a bipartite phosphopeptide binding site in
which the N-terminal phosphoserine of either p105 or IB
interacts more strongly than the C-terminal phosphoserine.
Heissmeyer et al. have reported that HA-p105 degradation
triggered by coexpression with FL-IKK2 and TrCP1 in 293
cells is unaffected by the introduction of a serine 932-to-ala-
nine mutation but blocked by a serine 927-to-alanine mutation
(8). Thus, HA-p105 proteolysis promoted by overexpressed
FL-IKK2 and TrCP1 can be triggered by serine 927 phos-
phorylation alone. In contrast, a serine 932-to-alanine muta-
tion delays HA-p105 proteolysis promoted by FL-IKK2 expres-
sion in NIH 3T3 fibroblasts (21) and completely blocks p105
proteolysis triggered by TNF- stimulation (Fig. 2A). Thus, in
these latter experimental models, HA-p105 must be phosphor-
ylated on both serines 927 and 932 for optimal signal-induced
proteolysis. It is likely that TrCP1 overexpression masks the
need for serine 932 phosphorylation by artefactually promoting
sufficient TrCP1 binding to HA-p105 that is phosphorylated
only on serine 927 (Fig. 7B). However, when ubiquitination is
mediated by endogenous SCFTrCP, phosphorylation of both
serines is required for optimal TrCP binding. The present
study therefore highlights the importance of determining the
function of phosphorylation sites on a protein where the par-
ticipating regulatory proteins (i.e., IKK and SCFTrCP) are
expressed at physiological levels, rather than relying solely on
transient overexpression experiments.
In conclusion, this study demonstrates that the TNF--in-
duced proteolysis of NF-B1 p105 involves the IKK complex-
mediated phosphorylation of serines 927 and 932 in the PEST
region, within a motif similar to that in the IKK target se-
quence of IB. Phosphorylation of both residues is shown to
be required for the efficient recruitment of TrCP, a subunit of
the SCF-type E3 ligase which promotes the ubiquitination of
phospho-p105 and triggers its subsequent proteolysis.
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